Categories
Change Password!
Reset Password!
Intravenous 5 mg Zoledronate decreases fracture risk yearly, and 5 mg every two years halts bone loss, although the optimal dosing regimens for these implications are unpredictable.
Zoledronate is an intravenously administered
bisphosphonate that has been used to reduce fracture risk in osteoporosis. But
the optimal dosing regimen is still uncertain. Intravenous Zoledronate 5 mg
annually reduces the risk of fracture while 5 mg every 2 years prevent bone
loss. Therefore, the results of the present study demonstrated that the
antiresorptive activity of single Zoledronate doses of 1–5 mg persist for at
least 3 years in postmenopausal women with osteopenia.
Intravenous 5 mg Zoledronate decreases fracture risk
yearly, and 5 mg every two years halts bone loss, although the optimal dosing
regimens for these implications are unpredictable.
One hundred sixty females in their late postmenopause
with osteopenia were selected and obtained a single baseline dose of placebo or
1 mg, 2.5 mg or 5 mg of Zoledronate. Change in the spine bone mineral density
(BMD) was taken as the primary endpoint and changes serum markers of bone
turnover and hip BMD were considered as secondary endpoints.
The markers of bone turnover decreased, and BMD increased
in a dose-dependent manner with Zoledronate. After two years, the 1-mg, 2.5-mg
and 5-mg Zoledronate enhanced spine BMD and total hip BMD over placebo by (5.0%
and 2.6%), (5.7% and 4.1%), and (5.7% and 4.7%), respectively.After 5
years, the 1-mg, 2.5-mg and 5-mg
Zoledronate enhanced (2.0% and 1.8%), (2.2% and 2.8%), and (5.1% and 5.4%)
spine BMD and total hip BMD over placebo, respectively. In 1-mg, 2.5-mg, and
5-mg group, BMD persisted above baseline values for 2–3 years, 3–4 years, and
at least five years, respectively.
The antiresorptive activity of single 1–5 mg Zoledronate
continues for at least three years within postmenopausal women with osteopenia.
CMAJ. 2017 Sep 11; 189(36): E1130–E1136.
Duration of antiresorptive activity of Zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial
Andrew Grey et al.
Comments (0)